Personalized protease assay to measure protease activity in neoplasms
First Claim
1. An ex vivo method for detecting the presence of one or more protease activities in a neoplasia sample from a subject with cancer comprising:
- a) combining ex vivo a tissue sample from a subject with cancer with a molecule of the structure A-X-B-C, whereinB is a peptide portion of about 5 to about 20 basic amino acid residues, which is suitable for cellular uptake,A is a peptide portion of about 2 to about 20 acidic amino acid residues, which when linked with portion B is effective to inhibit or prevent cellular uptake of portion B, andX is a cleavable linker of about 2 to about 100 atoms joining A with B, where X is cleavable under physiological conditions, andC is a detectable moiety; and
b) detecting cleavage of A-X-B-C by detecting a change in said detectable moiety C, wherein said change in C is indicative of cleavage, said cleavage is indicative of the presence of one or more protease activities in said tissue sample, and the presence of the protease activity is indicative that said tissue sample is a neoplasia sample.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. In some embodiments, a MTS molecule disclosed herein has the formula (A-X-B-C), wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and C is a detectable moiety.
57 Citations
33 Claims
-
1. An ex vivo method for detecting the presence of one or more protease activities in a neoplasia sample from a subject with cancer comprising:
-
a) combining ex vivo a tissue sample from a subject with cancer with a molecule of the structure A-X-B-C, wherein B is a peptide portion of about 5 to about 20 basic amino acid residues, which is suitable for cellular uptake, A is a peptide portion of about 2 to about 20 acidic amino acid residues, which when linked with portion B is effective to inhibit or prevent cellular uptake of portion B, and X is a cleavable linker of about 2 to about 100 atoms joining A with B, where X is cleavable under physiological conditions, and C is a detectable moiety; and b) detecting cleavage of A-X-B-C by detecting a change in said detectable moiety C, wherein said change in C is indicative of cleavage, said cleavage is indicative of the presence of one or more protease activities in said tissue sample, and the presence of the protease activity is indicative that said tissue sample is a neoplasia sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
Specification